GK01 clinical trials
How each study uses GK01 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the GK01 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- GK01 Injection
- 6
Studies by the year they started
6 studies that test it; most in 2026 (4)
| Year | Studies |
|---|---|
| 2025 | 2 |
| 2026 | 4 |
Who runs them
Industry 4 · Other 2
Beijing Geekgene Technology Co., LTD (4) · Tianjin Medical University Cancer Institute and Hospital (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test GK01.
- Dec 2026A Clinical Study GK01 Injection in Subjects With Advanced Malignant Solid TumorsPhase 1 · Beijing Geekgene Technology Co., LTD
- Feb 2027A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.Early Phase 1 · Beijing Geekgene Technology Co., LTD
- Mar 2027A Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.Early Phase 1 · Beijing Geekgene Technology Co., LTD
Studies
Open first, then newest update. How each study uses GK01 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Clinical Study GK01 Cell Injection in Subjects With Advanced Lung CancerNot yet recruitingEarly Phase 1Beijing Geekgene Technology Co., LTDNCT07673419Written as GK01 Injection
- A Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.Not yet recruitingEarly Phase 1Beijing Geekgene Technology Co., LTDNCT07412665Written as GK01 injection
- A Clinical Study GK01 Injection in Subjects With Advanced Malignant Solid TumorsNot yet recruitingPhase 1Beijing Geekgene Technology Co., LTDNCT07482319Written as GK01 injection
- A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.RecruitingEarly Phase 1Beijing Geekgene Technology Co., LTDNCT07414316Written as GK01 Injection
- A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment of Solid TumorsRecruitingPhase 1Tianjin Medical University Cancer Institute and HospitalNCT07351903Written as GK01 Injection
- A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid TumorRecruitingPhase 1Tianjin Medical University Cancer Institute and HospitalNCT06954558Written as GK01 Injection